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Respiratory distress syndromePulmonary surfactant (PS) is characterized by a highly conserved lipid composition and the formation of unique
multilamellar structures within the lung. An unusually high concentration of DPPC is a hallmark of PS and is crit-
ical to the formation of a high surface area, stable air/water interface; the unusual lipid polymorphisms observed
in PS are dependent on surfactant proteins, particularly lung surfactant protein B (SP-B). The molecular mecha-
nisms of lipid trafﬁcking and assembly in PS remain largely uncharacterized. Using 2H and 31P NMR, we charac-
terize the dynamics and polymorphisms of the major lipid species in native PS and synthetic lipid mixtures as a
function of SP-B1-25 addition. Our ﬁndings point to increased dynamics and a departure from a lamellar behavior
for DPPC on addition of the peptide, consistent with our observations of DPPC phase separation in native surfac-
tant. The monounsaturated lipids POPC, POPG and POPE remain in a lamellar phase and are less affected than
DPPC by surfactant peptide addition. Additionally, we demonstrate that the properties of a native PS can be suc-
cessfully mimicked by using a fully synthetic lipid mixture allowing the efﬁcient evaluation of peptidomimetics
under development for PS replacement therapies via NMR spectroscopy. The speciﬁcity of the dynamic changes
in DPPC relative to POPC suggests the importance of tuning partitioning properties in successful peptidomimetic
design. This article is part of a Special Issue entitled:NMRSpectroscopy for Atomistic Views of Biomembranes and
Cell Surfaces. Guest Editors: Lynette Cegelski and David P. Weliky.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Mammals require high oxygenuptake,which is facilitated by the large
inner surface area of the lung at 300 cm2 per cubic centimeter [1]. A lipid/
protein complex known as pulmonary surfactant (PS) lines the inside of
the alveoli and reduces the work of breathing byminimizing surface ten-
sion [2]. Respiratory Distress Syndrome (RDS) occurs in premature in-
fants, who produce inadequate amounts of PS, as well as in olderlung surfactant extract; SP-B,
espiratory distress syndrome;
PPC-d62, 1,2-d62-dipalmitoyl-sn-
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ctroscopy for Atomistic Views of
sics, Troy University, Troy, ALchildren, due to low PS activity caused by lung injury [3]. PS is synthe-
sized, processed, stored, secreted, and recycled by type II pneumocytes.
It is secreted to the alveolar subphase as specialized organelles known
as lamellar bodies (LB) and recycled every 5–10 h. Secreted LB can fuse
to form tubular myelin (TM) while some LBmaintain their packed struc-
ture; both TM and LB contribute to the in vivo formation of the interfacial
ﬁlm important for oxygen exchange by unraveling and adsorbing onto
the air/water interface [4]. The molecular level processes by which PS
lipids are trafﬁcked to the air/water interface have been explored in sev-
eral recent in vitro studies [5–9]. A fully saturated, surface stable phos-
pholipid, dipalmitoylphosphatidylcholine (DPPC), found at high levels
in PS, is thought to be the major component of the surface ﬁlm; whether
it is speciﬁcally trafﬁcked to the interface or most of the non-DPPC com-
ponents of PS are squeezed out during the compression/expansion cycles
leaving a DPPC-rich surface ﬁlm or a combination of these processes
occur in the PS cycle in vivo is unknown [4]. The molecular level details
of the unusual dynamics and organization of LB and TM in the aqueous
phase also remain poorly characterized.
PS is an ideal system for studying the molecular basis of protein me-
diated lipid trafﬁcking and/or assembly in an aqueous environment. Its
simple lipid and protein composition (relative to the plasmamembrane)
is highly conserved among mammalian species, with lipids making up
N90% of the LB and TM. A summary of the lipids found in PS is presented
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dylcholines) make up ~85% of total PS phospholipids; almost half of
the phosphatidylcholine component is 1, 2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC). The two saturated acyl chains of DPPC enable
it to be packed tightly in the monolayer at the air/water interface; the
stability of DPPC monolayers to lateral pressure during compression is
thought to be critical to the integrity of this interface in the lung. The
melting temperature of neat DPPC is 41 °C; the remaining PC lipids are
monounsaturated and likely increase the ﬂuidity of the DPPC rich PS, ac-
celerating lipid trafﬁcking and surface ﬁlm formation [11]. While LB and
TMare primarily lamellar, they do not have the sameﬂuid consistency as
cell membranes and their multilamellar structures are packed more
tightly together than is typically observed for other lipid assemblies
(e.g. intracellular organelles); it has been hypothesized that non-
lamellar polymorphisms, such as the cubic or hexagonal phases, may
play a crucial role in the organization and function of PS [13].
Although lipids underpin the macromolecular assemblies important
to PS function, their unique properties are dependent on low levels of
surfactant proteins. In particular, surfactant protein B (SP-B), which is
highly hydrophobic and present at low levels (b2% byweight), is critical
to LB/TM integrity and the formation of a viable air/water interface [14,
15]. Humanswith genetic SP-B dysfunction die soon after birth as do ge-
netically engineered SP-B null mice. SP-B is a particularly challenging
protein to produce or isolate due to its high hydrophobicity, so animal
sources of PS are commonly used in treating RDS, posing a risk of infec-
tion or immune response [16]. In particular, calf lung surfactant extract
(CLSE) is a surfactant replacement therapy prepared from chloroform
extracts of lavaged PS from calf lungs [2]. It is commonly administered
to premature infants with RDS under the name Infasurf. The lipids in
CLSE are unusually surface active and form unique aqueous assemblies
similar to native PS due to low levels of surfactant proteins SP-B and
SP-C. CLSE contains 93% phospholipid, 5% cholesterol and neutral lipids,
and 2% SP-B and SP-C by weight and thus closely mimics human PS.
Given the tremendous importance of SP-B to PS function, surfactant
replacement methods employing simple surface-active peptide analogs
of SP-B have also been investigated as they can be easily produced with
high yield and purity. SP-B1-25 is an amphipathic peptide composed of
the ﬁrst 25 amino acids of the N-terminus of SP-B which retains much
of the biological activity of full length SP-B and is more resistant to inhi-
bition by plasmaproteins inﬁltrating the lung during injury [17–22]. Un-
derstanding how it functions in the PS lipid environment would allow
the development of mimetics which are even more stable. CD and
FTIR indicate the presence of helical structure in the C-terminal portion
of SP-B1-25when it is associatedwith lipidmonolayers [20]; the very hy-
drophobic N-terminal tail of SP-B1-25 enables rapid insertion into lipid
ﬁlms [8]. Previously we have shown that the ﬁrst several amino acids
are critical to the induction of uncommon lipid polymorphisms by SP-
B1-25 in synthetic binary lipid systemswith distinct differences between
DPPC/POPG and POPC/POPG mixtures [9]. These results led us to study
lipid polymorphisms in more complex lipid mixtures, including thera-
peutic CLSE, to gain a deeper understanding of lipid behavior in PS.
The goals of this study are threefold: 1) to individually characterize
the dynamics of the major lipid species in therapeutic CLSE, 2) to com-
pare lipid dynamics in CLSE to a completely synthetic lipid systembased
on PS composition, and3) to examinehow lipid dynamics and organiza-
tion are affected by the addition of the PS peptide SP-B1-25 via 31P and 2HTable 1
Lipid composition of native PS and lipid mixtures used in this study.
Phospholipid composition (%total) [% disaturated] Cholesterol
Source PC LPC SM PG PI PS PE LBPA (%chol/PL)
Human 80.5 [47.7] Tr 2.7 9.1 2.6 0.9 12.3 NR 7.3
Bovine 79.2 [49.9] Tr Tr 11.3 [33.3] 1.8 Tr 3.5 2.6 3
CLSET N75 [N60] NR NR NR NR NR NR NR NR
CSLES 76.2 [62.5] – – 14.3 – – 9.5 – 9.5static ssNMR experiments. 31P spectroscopy allows monitoring of lipid
dynamics and polymorphisms for all lipid species in a given sample
while 2H spectroscopy allowsmonitoring of the dynamics and polymor-
phisms of individual lipid species that are deuterium enriched and in
particular the dynamics of the deuterated lipid acyl chains.2. Materials & methods
2.1. Materials
DPPC, POPC, POPG, POPE, DPPC-d62, POPC-d31, POPG-d31 and POPE-
d31 were purchased as chloroform solutions from Avanti Polar Lipids
(Alabaster, AL) and quantiﬁed by phosphate analysis (Bioassay Systems,
Hayward, CA); cholesterol in powder form was also purchased from
Avanti. Research grade calf lung surfactant extract (CLSE) was gener-
ously provided as a gift from ONY, Inc. (Amherst, NY). CLSE is a chloro-
form extract of natural surfactant from calf lungsmanufactured byONY,
Inc., as the pharmaceutical drug product Infasurf. Upon receipt, the chlo-
roformwas evaporated and CLSEwas lyophilized for longer storage sta-
bility. CLSE contains 93–101 mg/ml of total phospholipid and ~1.3 and
~0.7 mg/ml of surfactant proteins B and C (SP-B and SP-C), respectively.
Unless otherwise stated, other reagentswere purchased fromFisher Sci-
entiﬁc (Hampton, NH) and used as received.2.2. Biochemical separation of CLSE lipids and proteins
To make samples of CLSE lacking surfactant proteins, the proteins
were separated from the lipids by gel permeation chromatography
with a Sephadex LH-20 (GE Healthcare) resin and 95:95:10 chloro-
form:methanol:0.1 NHCl (v/v/v) as the running solvent using previous-
ly established methods [23]. Eluent fractions were assayed by
phosphate and protein analyses. Inorganic phosphate was liberated
from the phospholipids and quantiﬁed to determine phospholipid con-
centration via a colorimetric assay (Bioassay systems) [24]. Protein con-
tent was assayed via the Amido Black Protein Assay [25,26]. These
assays are sensitive to μg quantities and were used to monitor the sep-
aration. Fractions containing only protein or only phospholipid were
separately pooled and extracted into chloroform to remove acid; frac-
tions containing both lipids and proteins were pooled, concentrated
and run over the column a second time. Phosphate and protein assays
indicated successful separation of CLSE lipids andproteins after a second
pass through the column. Due to the small, undetectable concentration
of cholesterol in the tail end of the eluentwith each run, the columnwas
ﬂushedwith an additional volume of chloroform:methanol:0.1 N HCl at
the end of each separation to recover the cholesterol. Concentrated cho-
lesterolwas identiﬁed by TLC and the collected cholesterolwas added to
the phospholipid fractions. The combined lipid fractions were dried
with nitrogen gas and then lyophilized from cyclohexane. Actual lipid
concentrations for the purpose of making NMR samples were deter-
mined after combining all lipid fractions from every pass through the
column. The amount of protein isolated was too small for the purposes
of this study and was not used further.2.3. Preparation of synthetic lipid mixtures
A synthetic PS lipid system was also studied for comparison to CLSE
and earlier studies of the binary mixture 4:1 DPPC/POPG [7–9]. The
phospholipids were purchased as chloroform solutions and mixed
after verifying their concentrations by phosphate analysis (Bioassay
Systems, Hayward, CA). Cholesterol was obtained as a dry powder and
dissolved in chloroform. Appropriate volumes of lipid chloroform solu-
tions were mixed to give ﬁnal lipid molar ratios of 10:6:3:2:2 DPPC/
POPC/POPG/POPE/chol for the synthetic PS lipid mixture, denoted
CLSES.
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SP-B1-25, (FPIPLPYCWLCRALIKRIQAMIPKG) was synthesized via
solid-phase peptide synthesis, puriﬁed by RP-HPLC, and veriﬁed by
mass spectrometry (m/z = 2928). To ensure that only peptide mono-
mers were present, TCEP was added to the peptide in methanol and
the monomeric peptide was isolated by using size-exclusion chroma-
tography. The monomer was then diluted into ammonium acetate, pH
8, and oxidized overnight; a purely monomeric peptide solution was
veriﬁed by non-reducing SDS-PAGE gel analysis. The peptide solution
was then lyophilized and dissolved in methanol to yield a ~1 mM
stock solution and quantitated by UV analysis.
2.5. Preparation of NMR samples
Samples were made with therapeutic CLSE (as received from ONY
with both lipids and proteins present, denoted CLSET), CLSE lipids after
removal of proteins (CLSEL), and by combining pure lipids in chloroform
based on the lipid composition of CLSE (CLSES). Acyl chain deuterated
lipids, DPPC-d62, POPC-d31, POPG-d31, and POPE-d31, were added to
the CLSE and synthetic lipid mixtures as reporters in the 2H NMR exper-
iments. The animal derived PS samples contained 20–50 mg of CLSE
(lipids only for CLSEL or with SP-B and SP-C also present for CLSET)
with 2–5 mg added deuterated phospholipid (e.g. 10% of total lipids).
For peptide containing samples, SP-B1-25 in methanol was added to
the lipid chloroform solutions resulting in P/L ratios ranging from
1:100 to 1:20. Samples were dried under a stream of nitrogen while in
a water bath at 45–50 °C; the resulting ﬁlms were suspended in warm
cyclohexane (45–50 °C), ﬂash frozen in nitrogen, and lyophilized over-
night to remove residual solvent. For each solid-stateNMR sample, ~15–
50 mg of peptide–lipid powder was placed in a 5 mm diameter NMR
tube and 200 μL of buffer containing 50 mM HEPES, pH 7.4, 140 mM
NaCl, and 1mMEDTA in 2H depletedwater (Cambridge Isotopes, Ando-
verMA)was added. The hydrated dispersions (inNMR tubes)were sub-
jected to 5 freeze–thaw cycles with gentle vortexing to form MLVs.
2.6. Solid state NMR analysis
31P and 2H NMR data were collected on a 500 MHz Bruker DRX sys-
tem (Billerica, MA) with a 5 mm BBO probe. A temperature calibration
using methanol and ethylene glycol standards was performed before
data collection; variable temperature spectra for POPC and DPPC stan-
dards containing 10% deuterated lipid conﬁrmed the calibration with
phase transitions at−2 and 41 °C, respectively. For the 31P NMR exper-
iments, spectra were collected by using a Bloch decay pulse sequence to
minimize T2 relaxation effects due to lipid dynamics, with 25 kHz pro-
ton decoupling applied during signal acquisition. 31P Spectra were ac-
quired with 256–512 scans and a 5 s recycle delay between scans to
minimize RF sample heating. The 31P B1 ﬁeld was 52 kHz (4.85 μs 90°
pulse). 2H NMR spectra were collected by using a quad echo sequence
(90°-τ-90°-τ-acq with τ= 30 μs) with a 2H B1 ﬁeld of 42 kHz (5.95 μs
90° pulse). 2H spectra were acquired with 2 k–16 k scans and a 0.5 s re-
cycle delay between scans. Depaking of NMR data was accomplished
with previously published algorithms which simultaneously dePake
and determine macroscopic ordering in partially aligned lipid spectra
using Tikonov regularization [27]. Assignments of 2H resonances were
based on Petrache et al. [28].
3. Results
3.1. The major lipids in CLSE exhibit lamellar properties at physiologic
temperatures; DPPC has a higher melting temperature than the
monounsaturated lipids
CLSET (therapeutic CLSE as received without any puriﬁcation) was
combined with low levels of deuterated lipid to probe the behavior ofindividual lipid species within the CLSE environment, which includes
SP-B and SP-C. 2H and 31P NMR spectra of DPPC-d62, POPC-d31, POPG-
d31, and POPE-d31 containing CLSET (i.e. four separate samples) were
collected over a range of temperatures (Fig. 1 and Supplementary
Figures S-1 and S-2). A series of variable temperature 31P NMR spectra
were also collected on a CLSET sample that did not have any deuterated
lipid added (Figure S-2); the properties of this sample were indistin-
guishable from the samples containing deuterated lipids, verifying
that addition of small amounts of deuterated lipid does not change the
phase behavior of CLSET. The phase transition temperatures of the indi-
vidual lipid specieswere determined byﬁttingﬁrst-moment analyses of
2H NMR spectra collected every 5 °C over the range of −10 to 55 °C
(Table 2 and Figure S-1). The phase transitions are signiﬁcantly broader
than in pure lipid systems, in part due to the presence of cholesterol, and
agree with previous measurements of PS thermal behavior by differen-
tial scanning calorimetry [29]. While the phase transition temperature
of DPPC is much lower in CLSET compared to the pure lipid (28 vs.
41 °C), it still melts at considerably higher temperature than the
mono-unsaturated lipids, suggesting some phase separation in CLSET
of DPPC-enriched domains. The Tm values for POPC, POPG, and POPE
are similar, at 19–22 °C, and they exhibit similarly broadmelting ranges
suggesting that they are well mixed; their signiﬁcantly higher Tm rela-
tive to neat POPC or POPG suggests some mixing with DPPC and other
high melting species such as saturated fatty acids. At a physiologic tem-
perature, all the lipids exhibit typical lamellar, liquid–crystalline
lineshapes. The dePaked 2H spectra at 40 °C for the CLSET samples con-
taining deuterated lipids (Fig. 2) show greater order for DPPC-d62 acyl
chains compared to POPC-d31, POPG-d31 and POPE-d31, consistent
with its high melting temperature. Order parameter plots comparing
the various lipids are provided in Figure S-3.
3.2. The dynamics of the major lipids in CLSE are unchanged by
protein removal
The protein components of CLSE were removed via gel permeation
chromatography, and the lipid constituents of CLSE, denoted CLSEL,
were combinedwith individually deuterated lipids and again examined
by 2H and 31P NMR spectroscopy. The thermal behavior of the lipids in
CLSEL, as reported by 2H and 31P NMR measurements (Figs. 1 and Sup-
plementary Information), is remarkedly similar to that observed in
CLSETwithDPPCmelting at 28 °C in both preparations and the order pa-
rameter proﬁles for the individual lipid species agreeing within the
error bars of themeasurements (Figures S-3 and S-4). The 31P data indi-
cate a slightly larger fraction of lysophosphatidylcholine (LPC) lipid spe-
cies present, as evidenced by an isotropic resonance at 0 ppm, in the
CLSEL samples compared to the CLSET samples (Figure S-5), likely due
to using two separate batches of CLSE from ONY leading to small differ-
ences in the amount of lysolipids present. Small differences are also seen
between the spectra of themono-unsaturated lipids in the two prepara-
tions, but these primarily arise fromdifferences in bulk alignment of the
lipid vesicles in the high magnetic ﬁeld, which is very sensitive to sam-
ple hydration, rather than differences in lipid dynamics at themolecular
level. Depaked spectra,which correct for any changes in bulk alignment,
are identical between the two CLSE preparations (Fig. 2).
3.3. The lipid properties of CLSE are closely matched by a synthetic PS
lipid mixture
CLSE was also compared to a fully synthetic lipid mixture, denoted
CLSES (Table 1), containing lipid concentrations mirroring the major
lipids of CLSE (DPPC, POPC, POPG, POPE, and cholesterol), which allows
full knowledge of the lipid composition in the sample and better control
of relative concentrations. 2H and 31P NMR measurements (Figs. 1 and
S-6) indicate that in the ﬂuid phase the properties of the individually
deuterated lipid species mirror those of the deuterated lipids added to
CLSET and CLSEL with identical ordering of the acyl chains. However,
CL
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Fig. 1.DeuteriumNMR spectra for CLSE samples containing low reporter levels of A)DPPC-d62, B) POPC-d31, C) POPG-d31, andD) POPE-d31 obtained at the indicated temperatures. The top
row is from samplesmadewith native CLSE (containing low levels of SP-B and SP-C), themiddle row is after removal of the proteins from CLSE, and the bottom row is a syntheticmixture
of lipids designed to mimic the lipid composition of CLSE. The mono-unsaturated lipids exhibit a lower melting temperature compared to DPPC in the native CLSE regardless of protein
content. In the synthetic lipid mixture, less phase separation of DPPC is observed.
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talline phase at 25 °C, suggesting that there is no phase separation in the
synthetic system at lower temperatures and that minor, non-protein
species in CLSET and CLSEL are facilitating phase separation of DPPC.
Nonetheless, the bulk properties of CLSES are very similar, as shown
by 31P NMRmeasurements (Figure S-6), as are the dynamics of the indi-
vidual lipid species at physiologic temperatures. Notably, the dePaked
spectra of DPPC-d62 in CLSES, CLSEL, and CLSET environments at 40 °C
are indistinguishable (Fig. 2).
3.4. Addition of SP-B1-25 to CLSE lipids speciﬁcally alters the phase properties
of DPPC
CLSET preparations contain very low concentrations of SP-B and SP-
C, as does human PS. Given the low concentrations of these proteins, it is
likely that their effects on the collective dynamics of the lipids are min-
imal since there are approximately 400–800 lipidmolecules for each SP-
C or SP-Bmonomer [30]. Nonetheless, the possibility exists that the pro-
teins are trafﬁcking a small percentage of lipids in the bulk lamellar
sample, which is undetectable via the solid-state NMR experiments.
However, a larger P/L ratio couldmake the effects of surfactant proteinsTable 2
Lipid phase transition temperatures in CLSE.
Sample Tm (Tm of neat lipid) Observed melting range
CLSET/DPPC-d62 28.0 °C (41.4 °C) 15–30 °C
CLSET/POPC-d31 19.5 (−2.4) 0–25
CLSET/POPG-d31 21.8 (−2.0) 0–25
CLSET/POPE-d31 22.0 (28.0) 5–25more visible. To test this hypothesis, we added increasing amounts of
the PS peptide SP-B1-25 into the CLSE preparations to measure how
this peptide affects lipid dynamics in CLSE. This allowed us to change
the P/L ratio of the samples enough to noticeably affect the bulk behav-
ior of the lipids to develop amodel of how lower levels of SP-Bmay traf-
ﬁc lipids. An initial test adding 5 mol% SP-B1-25 to either CLSET or CLSEL
containing DPPC-d62 indicated the peptide had identical, noticeable ef-
fects on lipid dynamics in both samples (Figure S-7). These data further
indicate that we did not change the lipid phase behavior being studied
by removal of the small amounts of SP-B and SP-C; even when 5 mol%
SP-B1-25 is added to the two CLSE environments they remain
indistinguishable.
3.5. Addition of SP-B1-25 has similar effects on native and synthetic PS
lipid mixtures
For more systematic studies of the effect of peptide addition, we
employed CLSEL and CLSES samples. Fig. 3 shows via 2H NMR spectros-
copy the concentration effects of this peptide on lipid dynamics in
CLSEL and CLSES near physiologic temperature (38 °C). Variable temper-
ature spectra of the lipids as well as dePaked spectra and order param-
eter proﬁles at 40 °C are provided in the Supplementary Information
(Figures S-8, S-9 and S-10). In CLSEL, the Tm of DPPC-d62 increases
from 28.3 to 39.1 °C with increasing peptide concentration from 0 to
5 mol%. The bulk properties of the mono-unsaturated lipids are much
less affected, suggesting that the peptide facilitates phase separation,
particularly in CLSEL where some phase separation already occurs as re-
ported above. This interpretation is supported by the fact that for the
mono-unsaturated lipids acyl chain ordering decreases slightly with
peptide addition, as evidenced by a gradual narrowing of the 2H NMR
AC
CLSEL
CLSES
CLSET
CLSEL
CLSES
CLSET
CLSEL
CLSES
CLSET
CLSEL
CLSES
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B
D
Fig. 2.Depaked 2HNMRspectra for CLSE samples containing low reporter levels of A)DPPC-d62, B) POPC-d31, C) POPG-d31, andD)POPE-d31 at 40 °C. At this temperature all the lipids are in
the Lα phase, and the ordering of the individual lipid acyl chains within the different CLSE preparations is indistinguishable.
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lesterol in association with the mono-unsaturated lipids. In both CLSEL
and CLSES lipid environments, exchange broadening is seen for DPPC
at peptide concentrations of 3–5 mol% and physiologic temperature.
This indicates that the DPPC dynamics in the synthetic PS mixture
very closely mimic DPPC behavior in native PS, allowing facile, consis-
tent testing of peptidomimetic effects onDPPCdynamics in amodel sys-
tem for developing PS replacement therapies. For POPC and POPG, the
lipid dynamics in CLSEL and CLSES are largely indistinguishable up to
3 mol% SP-B1-25. However, at the highest concentration we tested,
5 mol%, the peptide is seen to also affect the bulk properties of theA B
Frequenc
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Fig. 3. Comparison via 2H NMR spectroscopy of the effects of SP-B1-25 addition on lipid dynamic
with themol%of peptide indicated. The samples contain low reporter levels of A)DPPC-d62, B) P
a clear broadening in the lamellar lineshapes leading to a loss of resolution for the individual d
mixture, the POPC and POPG lipids are also affected at the highest peptide concentration. Thismono-unsaturated lipids in CLSES. This is consistent with our observa-
tions above that there are subtle lipid phase separation dynamics in na-
tive CLSE likely due to small amounts of species not added to the
syntheticmixture, such as free fatty acids and lysolipids, or due to subtle
differences in phospholipid and cholesterol concentrations relative to
the CLSES we designed for this study. In summary, 1 mol% SP-B1-25
does not appreciably affect lipid dynamics in either CLSEL or CLSES envi-
ronments at physiologic temperatures. At 3 mol% peptide the lipid
phase behavior changes for DPPC-d62, but not for POPC-d31 and POPG-
d31. At 5 mol% peptide, DPPC-d62 is most affected and overall the 2H
NMR spectra for DPPC-d62 exhibit the most change with increasingC
y (kHz)
s at 38 °C in native CLSE (CLSEL) lipids (top) vs. a synthetic (CLSES) lipid mixture (bottom)
OPC-d31, andC) POPG-d31 tomonitor effects on the individual lipids.With peptide addition,
euterated acyl chain positions in DPPC is seen in both lipid environments; in the synthetic
is likely due to less phase separation of DPPC in the synthetic lipid mixture.
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lamellar phase lineshapes in CLSES.
3.6. The dynamics of DPPC on addition of SP-B1-25 to complex PS lipid
mixtures indicate the formation of a new lipid phase
In previous studies of the effects of SP-B1-25 addition to binary 4:1
DPPC/POPG mixtures on lipid dynamics, we saw DPPC lineshapes at
1 mol% peptide that are very similar to those in CLSEL or CLSES at
3 mol% peptide; at higher peptide concentration we saw the creation
of an isotropic lipid phase in the binary lipid mixture (Fig. 4) [9].
While we do not see the onset of isotropic dynamics for DPPC-d62 in
CLSEL or CLSES at even 5 mol% peptide, the similarities of the DPPC-d62
lineshapes in CLSEL or CLSES in losing sharp features for the individually
deuterated positions in the acyl chain is likely due to the exchange of
DPPC between lipid lamellae; the formation of an isotropic ﬂuid phase
is likely prevented by either the presence of cholesterol or the high per-
centage of mono-unsaturated lipids in the CLSE mixtures compared to
4:1 DPPC/POPG. To link our observations in this study to those of our
previous work, we also examined DPPC dynamics in 8:2:1 DPPC/
POPG/Chol. Fig. 4 shows 2H NMR spectra of DPPC-d62 as a function of
peptide concentration for the series of PS-like lipid mixtures of varying
complexity. Order parameter proﬁles and variable temperature spectra
are provided in Figures S-11 to S-14. Interestingly, in the ternary mix-
ture the peptide is again observed to induce an isotropic phase which
is in exchangewith a broader component, suggesting that the induction
of out-of-plane motions for DPPC is a hallmark of SP-B1-25 activity but
that the higher concentration of mono-unsaturated lipids in CLSE may
prevent the total conversation to a phase that is isotropic on the NMR
timescale.
4. Discussion
The experiments delineated in this study had two major purposes.
The ﬁrst was to guide efforts in developing synthetic lipid/peptide for-
mulations to replace CLSE and other animal derived lung surfactant0%
1%
3%
5%
A
C
B
D
Frequency (kHz)
0%
1%
3%
5%
Fig. 4.A comparison of the effects of SP-B1-25 addition onDPPC dynamics at 38 °C in A) na-
tive CLSE lipids (CLSEL), B) a synthetic lipidmixturemimicking CLSE, C) 8:2:1DPPC/POPG/
Chol (CLSES), andD) 4:1DPPC/POPG. The spectra inD have beenpreviously reported [9]. A
clear change inDPPC dynamicswith peptide addition is seen in all the lipid environments;
it ﬁrst appears as broadening in the lamellar lineshapes leading to a loss of resolution for
the individual deuterated acyl chain positions and culminates in an isotropic lineshape
in the simpler lipid mixtures.formulations; the secondwas to better understand themolecularmech-
anisms underlying PS function. With research grade CLSE generously
provided by ONY, Inc., we set out to systematically characterize the in-
dividual lipids in the CLSE environment and the effects of PS proteins
and a peptide mimetic on their dynamics. In prior work we have
shown that an analog of SP-B, SP-B1-25, affects the dynamics of PS lipids
in binary lipid systems, particularly the disaturated DPPC, as we ob-
served isotropic 2H ssNMR spectra for DPPC-d62 in 4:1 DPPC/POPG
even at physiologic temperatures with the addition of 5 mol% SP-B1-25
[9]. With this evidence of the induction of unusual polymorphisms by
SP-B1-25, we proceeded to develop a model of lipid lamellae fusing to-
gether to form a ﬂuid isotropic phase when greater amounts of the pep-
tide are present. This model was supported by dynamic light scattering
measurements showing the peptide-induced fusion of unilamellar ves-
icles. With this new perspective on possible lipid organization in PS, we
asked whether such a model could apply to a clinically used, non-
synthetic PS replacement therapy derived from a native source.
Lung surfactant replacements currently used in clinical settings vary
in origin, composition, and effect [31]. Animal derived PS formulations
have been very successfully used to combat RDS in premature infants,
but they raise concerns regarding purity, immunogenicity, and unifor-
mity [16,32]. The experiments described in this work took advantage
of a bovine PS source obtained via bronchiolar lavage, CLSE, which is
analogous to the clinically used drug Infasurf, as it is the closest formu-
lation to native surfactant available on the market [33]. One purpose
of this study was to evaluate if a synthetic PS replacement formulation
could exhibit properties similar to CLSE at the molecular level as a syn-
thetic replacementwould be ideal for treatment of RDS as it is more sta-
ble and has a longer shelf-life in addition to removing the risks of
immune response and infection with animal sources of PS. To this end,
we systematically characterized the organization and dynamics of the
major individual lipid species in native CLSE and a synthetic lipid mix-
ture designed to mimic CLSE.
Our initial characterization of CLSE via 2H ssNMR showed that the
phase behaviors of deuterated lipids in CLSET are similar and exhibit a
broad phase transition range. The broad Tm range from 10 to 30 °C is
consistent with what has been observed in DSC traces of PS extracts
[29]. While only lamellar lipid phases were observed, the Tm for DPPC
was higher than for the monounsaturated lipids, suggesting phase sep-
aration, and led us to further investigate the CLSE lipids without protein
present to examinewhether the lipids in CLSET (the therapeutic formu-
lation containing SP-B and SP-C) and CLSEL (CLSE after protein removal)
behaved similarly, which they did. This led us to examine whether a
fully synthetic lipid mixture based on the main lipids of CLSE, CLSES,
would also behave similarly. At physiologic temperatures, the major
lipids in the three lipid systems exhibited identical properties. However,
the phase separation of DPPC from the mono-unsaturated lipids at in-
termediate temperatures was not observed in CLSES, suggesting the im-
portance of minor lipid species (such as free fatty acids) to the bulk
properties of CLSE. In particular, palmitic acid, which is abundant in
CLSE, melts at ~63 °C, contributing to a higher Tm for associated lipids
[34]. Nonetheless, the similarity of the three lipid systems at physiologic
temperatures suggests that CLSES can serve as a well-controlled lipid
system for evaluating peptidomimetics designed for use in PS replace-
ment therapies; with the new insights we gained on phase separation,
it is likely that small modiﬁcations can be made in the composition of
CLSES, such as adding palmitic acid, allowing it to even more closely
mimic native CLSE.
Unfortunately our studies using CLSET did not yield particular in-
sights into the role of SP-B in altering lipid dynamics at physiologic con-
centrations. This is likely due to the very small percentage of SP-B
present in CLSET, at a P/L ratio of 1:1000.While a low protein concentra-
tion has proven effective in treating RDS, it does not measurably affect
the bulk properties of the lipids enough to be seen byNMR spectroscopy
experiments characterizing lipid dynamics. However, we note the P/L
ratios in PS replacement therapies under development using synthetic
209S. Farver et al. / Biochimica et Biophysica Acta 1848 (2015) 203–210peptide analogs are substantially higher. For example, Surfaxin, the ﬁrst
FDA-approved peptide-based PS replacement therapy, has a P/L ratio of
about 1:50 for KL4, a synthetic peptide mimic of the C-terminus of SP-B.
A peptide consisting of theﬁrst twenty-ﬁve amino acids of SP-B, SP-B1-25,
has also been demonstrated to retain the activity of full length SP-B as
seen in both animal studies of lung function and air/water interface stud-
ies of surface tension at similarly higher concentrations [16]. Since our
previous studies demonstrated that SP-B1-25 facilitates dynamics ex-
change between lipid lamellae leading to exchange broadening and
non-lamellar lipid polymorphisms in simple binary lipid mixtures, we
decided to use SP-B1-25, which can be easily made with high purity, as
amimic of SP-B to assay howhigher concentrations of a lipid-active pep-
tide might affect lipid dynamics in either native CLSE or more complex
synthetic lipid mixtures.
We observed that while SP-B1-25 affected the dynamics of all the
lipids to some extent, DPPC displayed the largest changes in dynamics,
particularly in CLSET; the mono-unsaturated phospholipids were
much less affected. In all the lipid mixtures, peptide addition led to
broadening of the DPPC lineshapes typical to lipids in a lamellar
phase; at the highest percentages of peptide added (3–5 mol%), resolu-
tion of the individual deurated positions in the acyl chains was
completely lost in both CLSET and CLSES. In the simpler binary and ter-
nary lipid mixtures, this broadening was seen at 1 mol% peptide and
progressed to markedly changed lineshapes with major isotropic com-
ponents at 3–5 mol% peptide concentrations. In our previous work
using DPPC/POPG, we have shown that this exchange broadening for
DPPC signals the onset of fusion of lipid lamellae culminating in an iso-
tropic ﬂuid phase. The fact that we see similar behavior in CLSET sug-
gests that peptide mediated exchange of DPPC between lipid lamellae
is a hallmark of SP-B1-25 and may be important to its function in PS ac-
tivity; It is notable that we do not see similar changes in POPC dynamics
in CLSET but they are seen in CLSES. This suggests that PS components
driving lipid phase separation, such as cholesterol or palmitic acid,
may act synergistically with SP-B1-25 leading to the selective trafﬁcking
of DPPC between lipid leaﬂets in the complex PS lipid network seen in
the aqueous subphase.
5. Conclusion
Lipid assemblies that undergo geometric rearrangement could have
a signiﬁcant impact on lipid transfer to the air/water interface in the
lung. The underlying aqueous, protein-containing hypophase in PS has
unusual physical properties due to low concentrations of surfactant pro-
teinswhich aid in trafﬁcking secreted PS to the surfaceﬁlm lining the al-
veoli. To date, most studies of PS have focused on the molecular
properties of themonolayer phospholipid ﬁlm at the air/water interface
or have investigated low resolution images of intact surfactant, such as
electron micrographs of rat intra-alveolar lung surfactant [35–38].
This study presents new insights pertaining to the aqueous PS reser-
voir below the air/water interface; using NMR spectroscopy and selec-
tively deuterated lipids, we are able to exclusively characterize the
behavior of individual lipid species found in PS. We ﬁnd that DPPC is
uniquely phase separated in native CLSE, regardless of whether physio-
logic concentrations of SP-B and SP-C are present. Using an SP-B mimic
with known PS activity, SP-B1-25, we are able to show that peptide addi-
tion to CLSE leads to unusual DPPC dynamics and further phase separa-
tion of DPPC into a unique lipid phase. We also show that a synthetic
lipid mixture designed to mimic native PS can faithfully reproduce
many of these observations, suggesting a straightforward approach for
assaying the potential of peptidomimetic formulations in PS replace-
ment therapy.
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